Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report) gapped up before the market opened on Monday. The stock had previously closed at $3.68, but opened at $3.81. Inventiva shares last traded at $3.5950, with a volume of 236,477 shares changing hands.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the company. Piper Sandler reiterated an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Guggenheim boosted their price target on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, September 15th. HC Wainwright decreased their price target on Inventiva to $14.00 and set a “buy” rating on the stock in a research note on Thursday, November 5th. Wall Street Zen upgraded Inventiva from a “sell” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, Weiss Ratings lowered Inventiva from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Inventiva has a consensus rating of “Moderate Buy” and an average target price of $14.67.
Inventiva Stock Performance
The business has a 50-day moving average price of $3.64 and a two-hundred day moving average price of $4.76.
Inventiva (NASDAQ:IVA – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The company had revenue of $0.75 million during the quarter. On average, research analysts forecast that Inventiva S.A. Sponsored ADR will post -0.75 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of IVA. Commonwealth Equity Services LLC grew its position in shares of Inventiva by 7.0% during the 3rd quarter. Commonwealth Equity Services LLC now owns 89,853 shares of the company’s stock worth $332,000 after buying an additional 5,857 shares during the period. Platt Investment Counsel LLC acquired a new position in Inventiva in the third quarter valued at approximately $45,000. China Universal Asset Management Co. Ltd. lifted its holdings in Inventiva by 78.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,600 shares of the company’s stock valued at $142,000 after buying an additional 17,000 shares during the period. Engineers Gate Manager LP lifted its holdings in Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after buying an additional 43,280 shares during the period. Finally, Seven Fleet Capital Management LP bought a new position in Inventiva in the first quarter valued at approximately $1,111,000. Institutional investors own 19.06% of the company’s stock.
Inventiva Company Profile
Inventiva S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders. Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial. The company expects topline trial results in Q4 2026 and, if results are positive, plans to pursue U.S. regulatory approval, with a potential commercial launch in 2028.
Featured Articles
- Five stocks we like better than Inventiva
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
